Adenosine production by human B cells and B cell-mediated suppression of activated T cells

Blood

Volumn 122, Issue 1, 2013, Pages 9-18

  Saze, Zenichiro ^a,b   Schuler, Patrick J ^a,c   Hong, Chang Sook ^a   Cheng, Dongmei ^d   Jackson, Edwin K ^d   Whiteside, Theresa L ^a,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROADENOSINE; 5' NUCLEOTIDASE; ADENOSINE; ADENOSINE TRIPHOSPHATE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD19 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; APYRASE; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; NT5E PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; AUTOREGULATION; B LYMPHOCYTE; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL SURFACE; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LYMPHOCYTE SUBPOPULATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL COMMUNICATION; CELL CULTURE; CYTOLOGY; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIGENS, CD; APYRASE; B-LYMPHOCYTES; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; RECEPTORS, PURINERGIC P1; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84883736768     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-482406     Document Type: Article

References (32)

1. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010;10(4):236-247.
2. Homann D, Tishon A, Berger DP, Weigle WO, von Herrath MG, Oldstone MB. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J Virol. 1998;72(11):9208-9216. (Pubitemid 28471867)
3. Golovkina TV, Shlomchik M, Hannum L, Chervonsky A. Organogenic role of B lymphocytes in mucosal immunity. Science. 1999;286(5446):1965-1968. (Pubitemid 129515907)
4. Fu YX, Huang G, Wang Y, Chaplin DD. B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med. 1998;187(7):1009-1018. (Pubitemid 28176401)
5. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol. 2006;176(6):3498-3506. (Pubitemid 43363997)
6. Hauser SL, Waubant E, Arnold DL, et al HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688. (Pubitemid 351240747)
7. Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G; International Roundtable on B cells as Therapeutic Target for Intervention. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev. 2009;9(2):82-89.
8. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123(1):66-73. (Pubitemid 46401511)
9. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83.
10. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122(1):62-74. (Pubitemid 46026695)
11. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood. 2008;111(11):5334-5341.
12. Chen LC, Delgado JC, Jensen PE, Chen X. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol. 2009;183(6):4094-4102.
13. Tu W, Lau YL, Zheng J, et al. Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood. 2008;112(6):2554-2562.
14. Biragyn A, Lee-Chang C. A new paradigm for an old story: the role of regulatory B cells in cancer. Front Immunol. 2012;3:206.
15. Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264-268.
16. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+ CD25highFOXP3+ regulatory T cells. J Biol Chem. 2010;285(10):7176-7186.
17. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem. 2010;285(36):27571-27580.
18. Schuler PJ, Schilling B, Harasymczuk M, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol. 2012;42(7):1876-1885.
19. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(21):6301-6311. (Pubitemid 350075018)
20. Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. Hoboken, NJ: Wiley; 1999
21. Wan YY, Flavell RA. How diverse - CD4 effector T cells and their functions. J Mol Cell Biol. 2009;1(1):20-36.
22. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012;119(19):4430-4440.
23. Cannons JL, Lu KT, Schwartzberg PL. Lymph node choreography: B cells take the lead. Nat Immunol. 2012;13(7):630-632.
24. Wang Y, Rothstein TL. Induction of Th17 cell differentiation by B-1 cells. Front Immunol. 2012;3:281.
25. Griffin DO, Rothstein TL. Human "orchestrator" CD11b(+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity. Mol Med. 2012;18:1003-1008.
26. Parekh VV, Prasad DV, Banerjee PP, Joshi BN, Kumar A, Mishra GC. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol. 2003;170(12):5897-5911. (Pubitemid 36682569)
27. Barankiewicz J, Ronlov G, Jimenez R, Gruber HE. Selective adenosine release from human B but not T lymphoid cell line. J Biol Chem. 1990;265(26):15738-15743.
28. Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111(1):251-259.
29. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. . International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev. 2011;63(1):1-34.
30. Rittiner JE, Korboukh I, Hull-Ryde EA, et al. AMP is an adenosine A1 receptor agonist. J Biol Chem. 2012;287(8):5301-5309.
31. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530-541.
32. Ring S, Enk AH, Mahnke K. Regulatory T cells from IL-10-deficient mice fail to suppress contact hypersensitivity reactions due to lack of adenosine production. J Invest Dermatol. 2011;131(7):1494-1502.